MX2022005654A - Preparacion que contiene anticuerpo. - Google Patents

Preparacion que contiene anticuerpo.

Info

Publication number
MX2022005654A
MX2022005654A MX2022005654A MX2022005654A MX2022005654A MX 2022005654 A MX2022005654 A MX 2022005654A MX 2022005654 A MX2022005654 A MX 2022005654A MX 2022005654 A MX2022005654 A MX 2022005654A MX 2022005654 A MX2022005654 A MX 2022005654A
Authority
MX
Mexico
Prior art keywords
preparation
antibody
antibodies
salt
present disclosure
Prior art date
Application number
MX2022005654A
Other languages
English (en)
Inventor
Naoka Hironiwa
Hitoshi Sasaki
Daisuke Kameoka
Toru Yoshizawa
Megumi Numata
So Yamaguchi
Hiroko Murata
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2022005654A publication Critical patent/MX2022005654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)

Abstract

La presente invención se refiere en una modalidad no limitante, a formulaciones liofilizadas que contienen un antagonista de IL-31 (por ejemplo, un anticuerpo anti-IL-31RA) como ingrediente activo, las formulaciones liofilizadas contienen además arginina y/o una sal de la misma y sacarosa y/o trehalosa. En otra modalidad no limitante, la presente descripción se refiere a formulaciones en solución que contienen un antagonista de IL-31 como ingrediente activo, conteniendo además las formulaciones en solución arginina y/o una sal de la misma. En otras modalidades no limitantes, la presente descripción se refiere a métodos para estabilizar un anticuerpo (por ejemplo, un anticuerpo anti-IL-31RA) en una formulación que contiene anticuerpos, métodos para suprimir la agregación de anticuerpos (formación de agregados) en una formulación que contiene anticuerpo, y métodos para reducir componentes con heterogeneidad de carga en una formulación que contiene anticuerpos, caracterizados los métodos porque la formulación se prepara para contener arginina y/o una sal de la misma, y/o sacarosa y/o trehalosa.
MX2022005654A 2019-11-20 2020-11-19 Preparacion que contiene anticuerpo. MX2022005654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019209851 2019-11-20
PCT/JP2020/043125 WO2021100794A1 (ja) 2019-11-20 2020-11-19 抗体含有製剤

Publications (1)

Publication Number Publication Date
MX2022005654A true MX2022005654A (es) 2022-06-22

Family

ID=75981291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005654A MX2022005654A (es) 2019-11-20 2020-11-19 Preparacion que contiene anticuerpo.

Country Status (13)

Country Link
US (3) US11260125B2 (es)
EP (1) EP4062933A4 (es)
JP (4) JP6845973B1 (es)
KR (2) KR102416078B1 (es)
CN (1) CN114728064A (es)
AR (1) AR120512A1 (es)
AU (1) AU2020387034A1 (es)
BR (1) BR112022006590A2 (es)
CA (1) CA3156713A1 (es)
IL (1) IL293099A (es)
MX (1) MX2022005654A (es)
TW (1) TW202128222A (es)
WO (1) WO2021100794A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980992C (en) 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5043008Y2 (es) 1972-08-19 1975-12-09
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
JP2898064B2 (ja) 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
GB9016440D0 (en) 1990-07-26 1990-09-12 Elopak Systems A laminate
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
EP0671951A4 (en) 1992-12-01 1997-05-21 Protein Design Labs Inc HUMANIZED ANTIBODIES REACTING WITH L-SELECTIN.
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
CN1241944A (zh) 1996-12-05 2000-01-19 乔治敦大学 具有抗病毒活性的鼠尾草种类的提取物
JPH11101542A (ja) 1997-09-29 1999-04-13 Sanyo Electric Co Ltd 冷蔵庫
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
CA2326755A1 (en) 1998-04-30 1999-11-04 Tanox, Inc. G-csf receptor agonist antibodies and screening method therefor
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
AU759689B2 (en) 1998-06-24 2003-04-17 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor proteins
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
EP1188830B1 (en) 1999-06-02 2010-01-20 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein ,nr10
AU7445900A (en) 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
CN1326880A (zh) 2000-06-06 2001-12-19 周伟中 双层站台火车站
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
PT1325115T (pt) 2000-06-26 2016-09-28 Zymogenetics Inc Recetor de citocina zcytor17
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
NZ528483A (en) 2001-04-05 2008-03-28 Astellas Pharma Inc Anti-osteopontin antibody and use thereof
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
PT1576112E (pt) 2002-01-18 2012-05-25 Zymogenetics Inc Multímeros de receptor de citocina zcytor17
CN100575482C (zh) 2002-01-18 2009-12-30 津莫吉尼蒂克斯公司 新的细胞因子zcytor17配体
ATE431406T1 (de) 2002-02-25 2009-05-15 Genentech Inc Neuer typ-1-cytokinrezeptor glm-r
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
MXPA04010795A (es) 2002-05-01 2005-03-07 Schering Ag Nuevos anticuerpos dirigidos al factor tisular como anticoagulantes.
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
WO2004091543A2 (en) 2003-03-04 2004-10-28 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
EP1606316A2 (en) 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
WO2005079566A2 (en) 2004-02-12 2005-09-01 Lexicon Genetics Incorporated Gene disruptions, compositions and methods relating thereto
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
EP1773391A4 (en) 2004-06-25 2009-01-21 Medimmune Inc INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
CA2591059C (en) 2004-12-28 2018-11-06 Innate Pharma Monoclonal antibodies against nkg2a
ES2579758T3 (es) 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
WO2006088955A2 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
US20060182743A1 (en) 2005-02-14 2006-08-17 Janine Bilsborough Methods of treating skin disorders using an IL-31RA antagonist
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
TW200718780A (en) 2005-06-10 2007-05-16 Chugai Pharmaceutical Co Ltd Sc(Fv)2 site-directed mutant
AU2007249713A1 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31Ra and OSMRb antagonists
ES2586825T3 (es) 2006-01-12 2016-10-19 Alexion Pharmaceuticals, Inc. Anticuerpos para OX-2/CD200 y usos de los mismos
CN101421303B (zh) 2006-03-23 2013-06-12 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
DK2047863T3 (da) 2006-06-08 2013-09-16 Chugai Pharmaceutical Co Ltd Middel til forebyggelse eller behandling af inflammatoriske sygdomme
ES2415655T3 (es) 2006-06-15 2013-07-26 The Board Of Trustees Of The University Of Arkansas Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
EP2759549B1 (en) 2006-09-01 2015-08-19 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
CN101600456A (zh) 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
RU2009120202A (ru) 2006-12-11 2011-01-20 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с il-13 расстройств
EP2069404B1 (en) 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
BRPI0807710B1 (pt) 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
WO2009007272A1 (en) 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Novel formulation
PH12018501459A1 (en) 2007-09-26 2019-11-11 Chugai Pharmaceutical Co Ltd Modified antibody constant region
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
CL2008002885A1 (es) 2007-09-26 2010-07-02 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
EP2241332A4 (en) 2007-12-05 2011-01-26 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT AGAINST PRITURE
EP2236604B1 (en) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
HUE036548T2 (hu) 2007-12-07 2018-08-28 Zymogenetics Inc IL-31-re specifikus humanizált antitest molekulák
KR20160062207A (ko) 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
WO2013012022A1 (ja) * 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
TW201537175A (zh) 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法
CA2980992C (en) * 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
GB201703063D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
BR112019021364A2 (pt) * 2017-04-11 2020-05-05 Kiniksa Phamaceuticals Ltd formulação estável de anticorpo anti-osmr
US20210196568A1 (en) 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos

Also Published As

Publication number Publication date
KR102416078B1 (ko) 2022-07-01
US11723976B2 (en) 2023-08-15
US20220125921A1 (en) 2022-04-28
US20220184210A1 (en) 2022-06-16
IL293099A (en) 2022-07-01
WO2021100794A1 (ja) 2021-05-27
AR120512A1 (es) 2022-02-16
TW202128222A (zh) 2021-08-01
EP4062933A1 (en) 2022-09-28
US11260125B2 (en) 2022-03-01
US20210322550A1 (en) 2021-10-21
JP2022116305A (ja) 2022-08-09
JP2021169448A (ja) 2021-10-28
JPWO2021100794A1 (ja) 2021-12-02
JP6845973B1 (ja) 2021-03-24
EP4062933A4 (en) 2023-12-13
JP6889344B2 (ja) 2021-06-18
CN114728064A (zh) 2022-07-08
KR20210064112A (ko) 2021-06-02
CA3156713A1 (en) 2021-05-27
AU2020387034A1 (en) 2022-06-02
KR20220098046A (ko) 2022-07-08
JP2021091704A (ja) 2021-06-17
BR112022006590A2 (pt) 2022-06-28

Similar Documents

Publication Publication Date Title
HRP20201090T1 (hr) Protutijela anti-icos
HRP20231456T1 (hr) Protutijela protiv c5 i njihova upotreba
MX2022005654A (es) Preparacion que contiene anticuerpo.
SG10201808837RA (en) Anti-egfr antibodies and antibody drug conjugates
MX2018003306A (es) Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.
SG10201808519VA (en) Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
HRP20201297T1 (hr) Stabilna formulacija anti-ifnar1
MX2021002190A (es) Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
MX2019012076A (es) Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
BR112018006140A2 (pt) anticorpo ou uma porção de ligação a antígeno do mesmo, composição farmacêutica, e, método para inibição de proliferação de células cancerígenas.
BR112016010706A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo
NZ705178A (en) Anti-prolactin receptor antibody formulations
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
MX2017009182A (es) Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas.
MX2018009341A (es) Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
BR112016020009A2 (pt) anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
EA200970880A1 (ru) Стабильные композиции на основе антител
EA201790239A1 (ru) Молекула-носитель для антигенов
MX2017012615A (es) Anticuerpo anti-notch4 humano.
MX2020002406A (es) Anticuerpo anti-epha4.
WO2016048188A8 (ru) Высокоаффиные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
WO2018102670A3 (en) Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down
RU2016148682A (ru) Антитела против рецептора-3 к эпидермальному ростовому фактору человека (her3), связывающиеся с бета-шпилькой her3